Browse more cannabis research, findings, methods, and limitations.
Kentucky BRFSS data showed 10% cannabis use prevalence (below national average), with 42% daily/near-daily use and most users citing medical reasons, even before legalization.
Pediatric study found CHS patients were older, had higher blood pressure, lower potassium, and positive drug screens compared to CVS patients, while imaging was rarely helpful for either condition.
Review of randomized controlled trials found 10 medications across 8 neurotransmitter systems showing promise for cannabis use disorder, though none yet has strong enough evidence for approval.
Matched-cohort study of 208 ACL reconstruction patients found no significant differences in opioid use or recovery outcomes between those with and without cannabis use disorder.
Case series of 9 adolescents found cannabinoid hyperemesis syndrome co-occurring with superior mesenteric artery syndrome, likely linked through CHS-related weight loss.
ABCD study of 10,092 early adolescents found multiple dimensions of gender diversity associated with higher odds of cannabis experimentation at ages 12-13.
Review examines how cannabis affects the cardiovascular system, highlighting increased heart rate, blood pressure changes, and the problem of patients concealing their use from doctors.
Evidence summary found prenatal cannabis exposure associated with attention problems, hyperactivity, memory challenges, and diminished academic performance in children, though confounders limit causal conclusions.
Analysis of ~383,000 patient portal messages found cannabis discussions shifted from drug screening concerns to patients seeking medical marijuana access after Pennsylvania legalized medical use.
Cannabis leaf extract reduced depression-like behavior and brain inflammation in mice, with effects attributed to the combined action of THCA and the terpene B-caryophyllene.
Study of 616 untreated substance users found cannabis use was not associated with suicidal thoughts, while methamphetamine and heroin use were strong independent predictors of suicidality.
Study of 133 children found prenatal tobacco exposure increased impulsive responding, but adding cannabis did not worsen effects. Unexpectedly, co-exposed children scored higher on short-term memory.
CBD improved social deficits (at 20 mg/kg) and reduced repetitive behaviors and hyperactivity (at 50 mg/kg) in a mouse model of autism, suggesting dose-dependent targeting of different symptoms.
Pilot study of telehealth counseling plus smartphone-based interventions for young cannabis users showed 100% engagement and 27% reduction in use days at 2-month follow-up.
Dutch economic analysis found pharmaceutical CBD is cost-effective for Lennox-Gastaut syndrome (21,493 euros/QALY) and cost-saving for Dravet syndrome, supporting reimbursement decisions.
Randomized controlled trial found CBD-rich cannabis extract significantly improved social interaction, anxiety, and agitation in 60 children with autism over 12 weeks, with minimal side effects.
Lab study found two cannabinoid receptor-activating compounds killed glioma cancer cells while sparing normal brain cells, working through the PI3K/Akt pathway.
Critical review found the cannabis "entourage effect," widely promoted in marketing, lacks strong scientific evidence as a stable and predictable phenomenon, cautioning against premature acceptance.
Mayo Clinic survey of 1,336 fibromyalgia patients found nearly half used cannabis, primarily for pain (82% reported improvement), fatigue, anxiety, and insomnia.
Analysis of 5,194 young adults found 1.1% had both cannabis use and social anxiety, strongly associated with other psychiatric disorders including panic disorder (OR up to 19.05).
Interviews with 16 postpartum women found fear of child protective services was the biggest barrier to disclosing cannabis use during pregnancy, compounded by perceived negative provider communication.
Nevada ER visits for cannabinoid hyperemesis syndrome doubled after recreational cannabis sales began in 2017, rising from 1.07 to 2.22 per 100,000 population.
Canadian survey of 13,527 cannabis users found that after legalization, only people with schizophrenia showed significant increases in daily use (9-fold higher odds), while other psychiatric groups showed no change.
Meta-analysis of 57 studies found prenatal cannabis exposure increased risks of preterm birth (68%), low birth weight (160%), and NICU admission (151%), with limited cognitive effects beyond attention problems.
Systematic review of 78 studies found cannabis use associated with increased depressive and manic symptoms, higher risk of developing mood disorders, and worse treatment outcomes.
Double-blind trial found the terpene d-limonene selectively reduced THC-induced anxiety and paranoia without affecting other THC effects, providing first rigorous human evidence for a cannabis entourage effect.
Population study found glioblastoma patients with cannabis use disorder had more surgical complications (32% vs 15%) and neurologic problems at follow-up, challenging claims of cannabis neuroprotection.
Ninety-day cannabinoid treatment in Alzheimer's model mice reduced amyloid plaque deposits, improved memory, and decreased brain inflammation markers.
In 183 veterans treated for PTSD + substance use, ongoing cannabis use didn't predict worse PTSD symptoms or dropout at subsequent assessments — though concurrent heavy drinking was associated with worse symptoms.
A cross-sectional survey found that chronic pain patients and physicians both supported expanded cannabis access, suggesting growing acceptance of cannabis as a pain management option among key stakeholders.
Lab study found CBD, CBN, and hemp extract did not harm human liver cells at consumer-relevant doses, though hemp extract showed modest effects on liver function markers at the highest concentration.
Review describes rising CHS prevalence with legalization, recommending benzodiazepines for acute attacks and amitriptyline (50-200 mg/day) for long-term prevention, with cannabis cessation as the definitive treatment.
National survey of 8,033 young adults found cannabis vaping associated with wheezing and cough at rates comparable to nicotine vaping — dual vaping had the worst respiratory symptoms.
Crossover trial found no meaningful next-day impairment in cognition, psychomotor function, or simulated driving after adults with insomnia took 10mg THC + 200mg CBD oil the previous evening.
Trial found oral fluid THC tests were mostly negative just 30 minutes after oral medicinal cannabis (poor sensitivity) and completely negative by 10 and 18 hours, suggesting low next-morning detection risk.
CBGA was the most potent cannabinoid at blocking TRPM7 ion channels, which are involved in cancer, stroke, and kidney disease, working through the channel's kinase domain.
Review of preclinical evidence finds multiple non-intoxicating cannabinoids beyond CBD can reduce gut pain and inflammation through TRP and ion channels, not just classical cannabinoid receptors.
Two Australian cases of opioid toxicity from THC vape products containing the potent synthetic opioid protonitazene, including one death, highlight a dangerous new contamination threat.
Interviews with 18 Swiss cannabis trial stakeholders revealed political pressures and power dynamics systematically shaped research design, illustrating "policy-based evidence" in drug policy.
Australian study of 222,534 mother-child pairs found maternal cannabis use disorder associated with three-fold higher autism risk in offspring, with stronger effects in males.
Meta-analysis of 36 studies and 18 million births found prenatal cannabis exposure associated with 2-3x higher risks of cardiovascular, GI, CNS, and genitourinary birth defects.
Meta-analysis of 14 studies found prenatal cannabis exposure associated with higher ADHD symptom scores and a 30% increased risk of autism, involving over 200,000 participants.
Blinded lab study found CBD and THC suppressed both pro-inflammatory Th17 cells and regulatory T cells in human immune cells, representing broad immunomodulation rather than simple anti-inflammatory action.
Italian study of 335 impaired driving recidivists found polydrug use doubled recidivism risk, with the cocaine-cannabis combination specifically flagged as a risk factor.
Prenatal CBD oil (THC-free) prevented autism-like behaviors in all three core symptom domains in male rat offspring from a neuroinflammation-based ASD model.
Mouse colitis study found CB2 agonist HU308 matched high-dose CBD efficacy at 1/24th the dose, with both normalizing gut inflammation and GLP-1 hormone levels.
Interviews with cannabis managers in Lesotho found regulatory delays and exclusion of small enterprises threatening Africa's first legal medicinal cannabis sector.
Study of 470 psychiatrically hospitalized adolescents found cannabis vaping as the primary use method associated with 2.4x higher odds of recent suicide attempt.
Mouse study found synthetic cannabinoid AMB-FUBINACA toxicity was CB1-dependent, worsened by the party drug pFPP, and partially treatable with the CB1 antagonist rimonabant.
Small feasibility trial found CBD-dominant cannabis oil was safe and well-tolerated over 21 weeks in 12 long COVID patients, with no serious adverse events and 100% adherence.